NASDAQ : EQ
Equillium, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.42 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 111.28M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 107.36M |
| Enterprise Value | 50.78M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 78.37M |
| Shares Outstanding | 78.37M |
| Shares Change (YoY) | +157.46% |
| Shares Change (QoQ) | +16.13% |
| Owned by Insiders (%) | 8.27% |
| Owned by Institutions (%) | 43.17% |
| Float | 59.18M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.55 |
| P/TBV Ratio | 1.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 23.40 |
| Quick Ratio | 23.07 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -58.98% |
| Return on Assets (ROA) | -33.95% |
| Return on Invested Capital (ROIC) | -38.97% |
| Return on Capital Employed (ROCE) | -34.35% |
| Weighted Average Cost of Capital (WACC) | 14.72% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.20M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.92 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.77 |
| 200-Day Moving Average | 2.08 |
| Relative Strength Index (RSI) | 43.79 |
| Average Volume (20 Days) | 557,877 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.66M |
| Short Previous Month | 5.54M |
| Short % of Shares Out | 7.22% |
| Short % of Float | 9.56% |
| Short Ratio (days to cover) | 8.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.30M |
| Pretax Income | -18.01M |
| Net Income | -18.01M |
| EBITDA | -19.20M |
| EBIT | -19.30M |
| Earnings Per Share (EPS) | -$0.20 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 57.16M |
| Total Debt | 584,000 |
| Net Cash | 56.58M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | 56.02M |
| Book Value Per Share | 0.88 |
| Working Capital | 55.50M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -19.97M |
| Capital Expenditures | -118,000 |
| Depreciation & Amortization | 101,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -20.09M |
| FCF Per Share | -$0.26 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -157.46% |
| Shareholder Yield | -157.46% |
| Earnings Yield | -14.36% |
| FCF Yield | -18.71% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.56 |
| Price Target Difference | 524.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |